Latest Clinical Trials News

Resonance Health reveals a robust growth strategy targeting $17 million revenue by FY26, powered by AI-enhanced medical imaging and global clinical trial services expansion.

Cryosite Limited reports a strong start to FY26 with a 22% revenue increase and a strategic warehouse acquisition that doubles capacity, positioning the company for sustained growth in clinical trial logistics.

INOVIQ Limited has launched an A$11.5 million capital raise to fast-track clinical validation and commercialization of its ovarian cancer screening test and advance its CAR-exosome therapeutic program targeting solid tumors.

PYC Therapeutics has reported encouraging pre-clinical results for its RNA therapy candidate PYC-002 targeting Phelan-McDermid Syndrome, supporting plans to enter human trials in 2026. The data demonstrate safety, brain distribution, and gene expression restoration in key disease regions.

Immutep Limited has confirmed 30 mg as the optimal biological dose for its immunotherapy efti, following FDA approval of Project Optimus requirements. This milestone paves the way for the US launch of its pivotal Phase III lung cancer trial.

Invion Limited has secured $0.8 million through convertible notes to repay its Lind Global Fund II LP facility and support working capital, positioning itself for potential global licensing deals of its Photosoft technology.

Prescient Therapeutics has bolstered its cash reserves to $12.3 million following a $9.8 million capital raise, while progressing its PTX-100 cancer therapy through global Phase 2 trials with encouraging early lymphoma results.

PYC Therapeutics has reported positive safety outcomes from its Phase 1 trial of PYC-001 for Autosomal Dominant Optic Atrophy, paving the way for a global Phase 1/2 study later this year.

Pathkey.AI’s TrialKey platform continues to validate its AI-driven clinical trial success predictions, with September 2025 seeing an average 43.6% share price increase across flagged biotech stocks.

Immutep Limited has enrolled over 170 patients in its global Phase III TACTI-004 trial for advanced non-small cell lung cancer, surpassing the threshold needed for a futility analysis expected in early 2026.

PainChek Limited has achieved a landmark FDA De Novo classification for its PainChek Adult App, positioning it as the first regulated medical device for pain assessment in the US aged care sector and opening a $100 million annual market opportunity.

Neurotech International has secured a key FDA designation for its lead drug NTI164, advancing its potential to treat Rett syndrome with regulatory and financial benefits.